1
J.A.S. is in the Division of Hematology/Oncology, Vanderbilt University Medical Center, Nashville, Tennessee 37232-6307, USA. Jeff.sosman@vanderbilt.edu
2
J.W.M. is in the Division of Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215. jmier@bidmc.harvard.edu.
Interleukin (IL)-2 can shrink tumors in patients with refractory melanoma and renal cancer, two of the deadliest types of solid tumors, but the use of IL-2 is limited by its high toxicity. A new drug reduces the side effects in mouse models and boosts the tumor-busting capacity of IL-2 (pages 750−755).
